Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Tracie Oliver Biography and Net Worth

Insider of Arrowhead Pharmaceuticals

Tracie Oliver, Chief Commercial Officer, joined Arrowhead in June 2022. Ms. Oliver has over 30 years of global experience in the biopharmaceutical industry leading both R&D and Commercial organizations. Prior to joining Arrowhead, she had her own consulting practice focused on development of commercial and development strategy for small biotech companies. She joined Shire Pharmaceuticals in 2016 through the acquisition of Baxalta and was Global Head of New Product Planning and Device Strategy. Prior to that she held several commercial roles at Baxter and Baxalta including establishing a new oncology franchise and leading the North America Immunology Business Unit and Autoimmune Franchise. Ms. Oliver began her career in the biopharmaceutical industry with Johnson & Johnson and served as head of Ortho Biotech Nephrology Business Unit in Canada, Ortho McNeil Neurologics, and McNeil Pediatrics in the USA and led an internal venture developing an allogeneic cell therapy for acute ischemic stroke. She received her BSc and MSc from Queen’s University in Kingston, Ontario and her MBA from the Shulich School of Business, York University, Toronto.

What is Tracie Oliver's net worth?: The estimated net worth of Tracie Oliver is at least $1.36 million as of July 3rd, 2023. Ms. Oliver owns 61,575 shares of Arrowhead Pharmaceuticals stock worth more than $1,362,039 as of April 26th. This net worth approximation does not reflect any other assets that Ms. Oliver may own. Additionally, Ms. Oliver receives an annual salary of $449,580.00 as Insider at Arrowhead Pharmaceuticals. Learn More about Tracie Oliver's net worth.
How old is Tracie Oliver?: Ms. Oliver is currently 62 years old. There are 6 older executives and no younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals is Dr. Bruce D. Given M.D., Chief Medical Scientist, who is 70 years old. Learn More on Tracie Oliver's age.
What is Tracie Oliver's salary?: As the Insider of Arrowhead Pharmaceuticals, Inc., Ms. Oliver earns $449,580.00 per year. There are 5 executives that earn more than Ms. Oliver. The highest earning executive at Arrowhead Pharmaceuticals is Dr. Christopher R. Anzalone Ph.D., CEO, President & Director, who commands a salary of $1,600,000.00 per year. Learn More on Tracie Oliver's salary.
How do I contact Tracie Oliver?: The corporate mailing address for Ms. Oliver and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Tracie Oliver's contact information.
Has Tracie Oliver been buying or selling shares of Arrowhead Pharmaceuticals?: Tracie Oliver has not been actively trading shares of Arrowhead Pharmaceuticals during the last ninety days. Most recently, Tracie Oliver sold 8,925 shares of the business's stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $35.31, for a transaction totalling $315,141.75. Following the completion of the sale, the insider now directly owns 61,575 shares of the company's stock, valued at $2,174,213.25. Learn More on Tracie Oliver's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 408,135 shares worth more than $13,514,007.79. The most recent insider tranaction occured on March, 20th when Director Hongbo Lu bought 1,000 shares worth more than $27,500.00. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 3/20/2024.

Tracie Oliver Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/3/2023	Sell	8,925	$35.31	$315,141.75	61,575

Tracie Oliver Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $22.12

$21.72

$22.36

50 Day Range

MA: $28.12

$21.87

$36.08

2 Week Range

Now: $22.12

$20.67

$42.48

Volume

617,025 shs

Average Volume

1,447,918 shs

Market Capitalization

$2.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Tracie Oliver Biography and Net Worth

What is Tracie Oliver's net worth?

How old is Tracie Oliver?

What is Tracie Oliver's salary?

How do I contact Tracie Oliver?

Has Tracie Oliver been buying or selling shares of Arrowhead Pharmaceuticals?

Who are Arrowhead Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?